RNLXY (Renalytix) 3-Month Share Buyback Ratio: 0.00% (As of Dec. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RNLXY Renalytix PLC RNLXY
44 GF Score
Price $4.20
GF Value $2.79
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Renalytix 3-Month Share Buyback Ratio?

Renalytix RNLXY +7.69% 44 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus rates RNLXY with a GF Score™ of 44/100 and a GF Value™ of $2.79 (Significantly Overvalued). The stock has 3 warning signs investors should review.

3-Month Share Buyback Ratio only apply to companies whose reporting frequency is 3 months.

RNLXY
44GF Score
Renalytix PLC RNLXY
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a 3-Month Share Buyback Ratio of 0.00 mean?
Renalytix (RNLXY) has a 3-Month Share Buyback Ratio of 0.00 as of Dec. 2025. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Renalytix and its competitors.
Is Renalytix's 3-Month Share Buyback Ratio too high?
Renalytix's current 3-Month Share Buyback Ratio is 0.00. Overall, Renalytix has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Renalytix's 3-Month Share Buyback Ratio compare to VEEV and BTSG?
Renalytix's 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Healthcare Providers & Services company?
A good 3-Month Share Buyback Ratio depends on the Healthcare Providers & Services industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Renalytix and its competitors. Renalytix's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renalytix stock overvalued right now?
Based on GuruFocus' analysis, Renalytix (RNLXY) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.79, compared to a current price of $4.20 — trading 50.5% above its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. Renalytix's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Renalytix (RNLXY), the current 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Renalytix (RNLXY) Overvalued in 2026?

Based on GuruFocus' analysis, Renalytix stock appears to be overvalued. The current stock price of $4.20 is trading 50.5% above its estimated GF Value™ of $2.79. GuruFocus considers Renalytix to be Significantly Overvalued.

Key valuation signals for RNLXY:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: $2.79 vs. price of $4.20 (50.5% above fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the RNLXY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Renalytix Business Description

Other Exchanges RENXF:USARENX:UK2O9:Germany
Address 2 Leman Street, London, GBR, E1W 9US
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.
44GF Score

Get the complete analysis for RNLXY

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.20
Price
$2.79
GF Value